<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004025</url>
  </required_header>
  <id_info>
    <org_study_id>TTFields-UM</org_study_id>
    <nct_id>NCT05004025</nct_id>
  </id_info>
  <brief_title>Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma</brief_title>
  <official_title>Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HonorHealth Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HonorHealth Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tumor Treating Fields targeted to liver metastases may improve outcomes for patients with&#xD;
      metastatic uveal melanoma treated with immune checkpoint inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uveal melanoma is the most common ocular malignancy for adults and despite effective&#xD;
      therapies, roughly 50% of patients will develop metastatic disease. Currently there is no&#xD;
      therapy to improve the prognosis of patients with metastatic disease and these patients are&#xD;
      usually treated with regimens used for cutaneous melanoma. Tumor Treating Fields is a new&#xD;
      type of anti-cancer therapy approved by the FDA for use in glioblastoma multiforme and&#xD;
      mesothelioma. TTF has been shown to activate the STING pathway leading to increased levels of&#xD;
      dendritic cells in regional lymph nodes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">August 29, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Tumor-Treating Fields in Combination with Immunotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>from the initiation of study treatment and through study completion, up to 1 year</time_frame>
    <description>evaluate the overall response rate of patients with mUM treated with TTF in combination with nivolumab and ipilimumab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Safety</measure>
    <time_frame>From the initiation of study treatment and through study completion, up to 1 year</time_frame>
    <description>Evaluate the safety of TTF in combination with nivolumab and ipilimumab (Number of patients who developed grade 3 treatment-related adverse events as assessed by CTCAE v5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>From initiation of study treatment until date of death from any cause, up to 100 months</time_frame>
    <description>to assess the median progression free survival and overall survival of treated patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>TTF Plus Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novacure Optune with Opdivo and Yervoy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Novocure Optune</intervention_name>
    <description>Novacure Optune with Opdivo and Yervoy</description>
    <arm_group_label>TTF Plus Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opdivo</intervention_name>
    <description>Novacure Optune with Opdivo and Yervoy</description>
    <arm_group_label>TTF Plus Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yervoy</intervention_name>
    <description>Novacure Optune with Opdivo and Yervoy</description>
    <arm_group_label>TTF Plus Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has histologically or cytologically confirmed metastatic uveal melanoma with&#xD;
             predominant liver involvement&#xD;
&#xD;
          2. Age 18 years or older and willing and able to provide informed consent&#xD;
&#xD;
          3. WOCBP must have a negative serum pregnancy test documented with 72 hours of first&#xD;
             administration of drug&#xD;
&#xD;
          4. Sexually active and WOCBP, patient and partner must agree to use adequate&#xD;
             contraception&#xD;
&#xD;
          5. Normal organ and marrow function&#xD;
&#xD;
          6. ECOG 0-1&#xD;
&#xD;
          7. Life expectancy of 3 months or greater&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of previous grade 3, life threatening immune related adverse event (irAE) from&#xD;
             prior checkpoint inhibitor therapy&#xD;
&#xD;
          2. Prior treatment with anti cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4) therapy&#xD;
             within 90 days of C1D1 of study treatment&#xD;
&#xD;
          3. Prior anti-cancer therapy (systemic, regional or radiation) within 2 weeks of C1D1 of&#xD;
             study treatment&#xD;
&#xD;
          4. AEs from prior anticancer therapies that have not resolved to grade 1 or less, other&#xD;
             than endocrine related irAEs for which patients are on appropriate replacement therapy&#xD;
             (ie hypothyroidism, adrenal insufficiency, type 1 diabetes)&#xD;
&#xD;
          5. History of or active autoimmune disease requiring systemic corticosteroid or&#xD;
             immunosuppressive therapy. (Patients who have limited autoimmune disease not requiring&#xD;
             systemic therapy or autoimmune disease that is unlikely to recur, such as ulcerative&#xD;
             colitis s/p colectomy, will be allowed to enroll.)&#xD;
&#xD;
          6. Serious medical risk factors involving any of the major organ systems such that the&#xD;
             Investigator considers it unsafe for the patient to receive an experimental research&#xD;
             drug.&#xD;
&#xD;
          7. Patient is unwilling or unable to comply with study procedures&#xD;
&#xD;
          8. Patients with implanted pacemaker, defibrillator, nerve stimulator or other active&#xD;
             electronic medical devices; sensitive to conductive hydrogels used on&#xD;
             electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS)&#xD;
             electrodes typically used for TTFields studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Justin Moser, MD</last_name>
    <phone>480-323-1350</phone>
    <email>jmoser@honorhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joyce Schaffer, MSN, AOCNS</last_name>
      <phone>480-323-1339</phone>
      <phone_ext>option #2</phone_ext>
      <email>Joschaffer@HonorHealth.com</email>
    </contact>
    <investigator>
      <last_name>Justin Moser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

